4//SEC Filing
PERSKY MARLA 4
Accession 0000899243-21-039328
CIK 0001867096other
Filed
Oct 4, 8:00 PM ET
Accepted
Oct 5, 7:44 PM ET
Size
14.0 KB
Accession
0000899243-21-039328
Insider Transaction Report
Form 4
PERSKY MARLA
Director
Transactions
- Award
Stock Option (Right to Buy)
2021-10-05+19,650→ 19,650 totalExercise: $12.50Exp: 2028-05-15→ Common Stock (19,650 underlying) - Award
Stock Option (Right to Buy)
2021-10-05+20,000→ 20,000 totalExercise: $10.00Exp: 2029-02-27→ Common Stock (20,000 underlying) - Award
Stock Option (Right to Buy)
2021-10-05+11,228→ 11,228 totalExercise: $4.68Exp: 2030-06-04→ Common Stock (11,228 underlying) - Award
Stock Option (Right to Buy)
2021-10-05+11,228→ 11,228 totalExercise: $3.90Exp: 2031-06-08→ Common Stock (11,228 underlying)
Footnotes (4)
- [F1]On October 5, 2021, pursuant to the transaction agreement dated as of May 24, 2021 ("Transaction Agreement") by and among Xeris Pharmaceuticals, Inc. ("Xeris"), Strongbridge Biopharma plc ("Strongbridge"), the Issuer ("HoldCo") and Wells MergerSub, Inc., a wholly owned subsidiary of HoldCo ("MergerSub"), HoldCo acquired the entire issued and to be issued ordinary share capital of Strongbridge (the "Acquisition"), and MergerSub merged with and into Xeris, with Xeris continuing as the surviving corporation and wholly owned subsidiary of HoldCo (the "Merger", and together with the Acquisition, the "Transaction").
- [F2](Continued from Footnote 1) At the effective time of the Merger (the "Merger Effective Time"), each option to purchase shares of Xeris common stock (the "Xeris Option") that was outstanding immediately prior to the Merger Effective Time, whether vested or unvested, was automatically converted into an option to purchase shares of HoldCo common stock (the "HoldCo Option"), on the same terms and conditions including any applicable vesting and exercisability requirements) as were applicable to such Xeris Option immediately prior to the Merger Effective Time, including that the number of shares of HoldCo common stock subject to the HoldCo Option is equal to the number of shares that were subject to the Xeris Option and the exercise price applicable to the HoldCo Option is the same as applied to the Xeris Option.
- [F3]These options are fully vested as of the date hereof.
- [F4]Such options will vest in full upon the earlier to occur of June 8, 2022 or the date of the Company's next annual meeting of stockholders.
Documents
Issuer
Xeris Biopharma Holdings, Inc.
CIK 0001867096
Entity typeother
Related Parties
1- filerCIK 0001270354
Filing Metadata
- Form type
- 4
- Filed
- Oct 4, 8:00 PM ET
- Accepted
- Oct 5, 7:44 PM ET
- Size
- 14.0 KB